QALWQuality-Adjusted Life Week (clinical trials)
References in periodicals archive ?
In comparison to anticancer drugs other than doxorubicin, PLD has a higher efficacy and cost than gemcitabine, the incremental cost-effectiveness ratio (ICER) observed for PLD was between 170 [euro] and 318 [euro] per QALW, which is between 8864 [euro] and 16581 [euro] per quality-adjusted life year (QALY) gained.
The cost-effectiveness of PLD was 170 [euro] and 318 [euro] per QALW while the cost-effectiveness of gemcitabine was between 317 [euro] and 589 [euro] per quality-adjusted life week Vici et al.